Cytoskeleton disruption by the metabolic inhibitor 3-bromopyruvate: implications in cancer therapy
admin-cespu
Bibliographic reference:
Azevedo-Silva J, Tavares-Valente D, Almeida A, Queirós O, Baltazar F, Ko YH, Pedersen PL, Preto A, Casal M. Cytoskeleton disruption by the metabolic inhibitor 3-bromopyruvate: implications in cancer therapy. Med Oncol. 2022 Jun 18;39(9):121. doi: 10.1007/s12032-022-01712-0
Azevedo-Silva J, Tavares-Valente D, Almeida A, Queirós O, Baltazar F, Ko YH, Pedersen PL, Preto A, Casal M. Cytoskeleton disruption by the metabolic inhibitor 3-bromopyruvate: implications in cancer therapy. Med Oncol. 2022 Jun 18;39(9):121. doi: 10.1007/s12032-022-01712-0